SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients
with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic)
disease-modifying anti-rheumatic drugs (DMARDs).